Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can chemotherapy harm the thyroid? a new study investigates

NCT ID NCT03177902

Knowledge-focused Sponsor: The First Affiliated Hospital of Bengbu Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This study follows 400 Chinese women with newly diagnosed breast cancer to see how often thyroid problems occur before and during chemotherapy. Researchers will measure thyroid function and structure at diagnosis and after at least four cycles of anthracycline or taxane-based chemotherapy. The goal is to understand whether chemotherapy affects the thyroid gland and to identify any related risks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Chemotherapy (anthracycline or taxane-based)
What this could lead to
If this study succeeds, it could help doctors predict and manage thyroid problems in breast cancer patients receiving chemotherapy, improving their overall care and quality of life.
What could go wrong
This is an observational study, so it cannot prove that chemotherapy causes thyroid issues. The results may not apply to all breast cancer patients, and the study only follows patients for a limited time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2017

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Newly diagnosed female breast cancer

Ages

18 to 85 years

Sex

Female participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Female patients with histologically or cytologically proven primary breast cancer; 2. Age \>18 years; 3. ECOG Performance Status: 0-2; 4. Life Expectancy: 3 months or more; 5. No previous anti-cancer therapy; 6. Be willing to undergo at least four cycles of anthracycline or taxane-based chemotherapy; 7. Adequate hematological, liver, and kidney functions. Exclusion Criteria: 1. Pregnancy or lactation; 2. History of other malignancy or secondary breast cancer; 3. History of thyroid disease; 4. History of drug addiction or abuse; 5. History of immunodeficiency disease; 6. Treatment with drugs capable of influencing thyroid gland functions within 3 months prior to study entry; 7. Nonmeasurable disease such as un-controlled diabetes, severe cardiovascular and cerebrovascular diseases; 8. Current, recent (within 4 weeks prior to study entry), or planned participation in any other clinical trials; 9. Inability to understand and agree to informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer female are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer female breast carcinoma thyroid gland disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer female Thyroid gland

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College

    RECRUITING

    Bengbu, Anhui, 233004, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.